Skip to main content
SpringerLink
Log in

HIV Infection and Pathogenesis: What About Chemokines?

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Several chemotactic cytokines, or chemokines, inhibit HIV replication by blocking or down regulating chemokine receptors that serve as entry cofactors for the virus. Although the role of chemokine receptors in HIV pathogenesis has been the subject of intense interest, chemokines are comparatively less seriously considered as potential correlates of protection from HIV infection and disease progression. However, a critical analysis of newly available data reveals substantial evidence to support a beneficial role for chemokines in HIV infection and disease. In this review we summarize the results of such studies and their promising implications for HIV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G-protein coupled receptor. Science 272:872–877, 1996

    Google Scholar 

  2. Alkhatib G, Combardiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC-CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955–1958, 1996

    Google Scholar 

  3. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath P, Lijun W, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodrosky J: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135–1148, 1996

    Google Scholar 

  4. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661–666, 1996

    Google Scholar 

  5. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667–673, 1996

    Google Scholar 

  6. Doranz BJ, Rucker J, Yi YJ, Smith RJ, Samson M, Peiper SC, Parmentier M, Cullman RG, Doms RW: A dual tropic primary isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2B as fusion cofactors. Cell 85:1149–1158, 1996

    Google Scholar 

  7. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856–1862, 1996

    Google Scholar 

  8. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722–725, 1996

    Google Scholar 

  9. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240–1243, 1996

    Google Scholar 

  10. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367–377, 1996

    Google Scholar 

  11. Zimmerman PA, Bucklerwhite A, Alkhatib G, Spalding T, Kubofcik JA, Combardiere C, Weissman DA, Cohen O, Rubbert AA, Lam G, Vaccarezza MA, Kennedy PE, Kumaraswami VA, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB, Murphy PM: Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor-5-studies in populations with contrasting clinical phenotypes, defined racial backgrounds, and quantified risk. Mol Med 3:23–36, 1997

    Google Scholar 

  12. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 3:338–340, 1997

    Google Scholar 

  13. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM: CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352:866–870, 1998

    Google Scholar 

  14. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tryon V, Clark RA, Dolan MJ, Ahuga SK: Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 4:786–793, 1998

    Google Scholar 

  15. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383–1388, 1997

    Google Scholar 

  16. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 186:1389–1393, 1997

    Google Scholar 

  17. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 186:1395–1400, 1997

    Google Scholar 

  18. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, DeClercq E, Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72–77, 1998

    Google Scholar 

  19. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factor produced by CD8+ T cells. Science 270:1811–1815, 1995

    Google Scholar 

  20. Dolei A, Biolchini A, Serra C, Curreli S, Gomes E, Dianzani F: Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1α, MIP-1β and RANTES β-chemokines. AIDS 12:183–190, 1998

    Google Scholar 

  21. Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S, Arthos J, Oliva A, Ehler L, Mizell S, Jackson R, Ostrowski M, Hoxie J, Offord R, Fauci AS: CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: Role of signal transduction. Proc Natl Acad Sci USA 95:11880–11885, 1998

    Google Scholar 

  22. Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A: Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 73:684–694, 1999

    Google Scholar 

  23. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P: Serum levels of RANTES and MIP-1α in HIV-positive long-term survivors and progressor patients. AIDS 10:1431–1432, 1996

    Google Scholar 

  24. Weiss L, Si-Mohamed A, Giral P, Castiel P, Ledur A, Blondin C, Kazatchkine MD, Haeffner-Cavaillon N: Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1α and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 176:1621–1624, 1997

    Google Scholar 

  25. Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A: Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection 26:100–103, 1998

    Google Scholar 

  26. McKenzie SW, Dallalio G, North M, Frame P, Means RT: Serum chemokine levels in patients with non-progressing HIV infection. AIDS 10:F29-F33, 1996

    Google Scholar 

  27. Krowka JF, Gesner ML, Ascher MS, Sheppard HW: Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin Immunol Immunopathol 85:21–27, 1997

    Google Scholar 

  28. Kakkanaiah VN, Ojo-Amaize EA, Peter JB: Concentrations of circulating beta-chemokines do not correlate with viral load in human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 5:499–502, 1998

    Google Scholar 

  29. Polo S, Veglia F, Malnati MS, Gobbi C, Farci P, Raiteri R, Sinicco A, Lusso P: Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 13:447–454, 1999

    Google Scholar 

  30. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587–592, 1992

    Google Scholar 

  31. Power CA, Clemetson JM, Clemetson KJ, Wells TN: Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 7:479–482, 1995

    Google Scholar 

  32. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W: Immunocytochemical localization of the chemokines RANTES and MIP-1α within human platelets and their release during storage. Int Arch Allergy Immunol 107:541–546, 1995

    Google Scholar 

  33. Bubel S, Wilhelm D, Entelmann M, Kirchner H, Kluter H: Chemokines in stored platelet concentrates. Transfusion 36:445–449, 1996

    Google Scholar 

  34. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P: Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J 12:79–89, 1998

    Google Scholar 

  35. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, Klavinskis L, Jones I, Doyle C, Ward R: Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2:767–775, 1996

    Google Scholar 

  36. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Jones I, Doyle C: Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Dev Biol Stand 92:225–235, 1998

    Google Scholar 

  37. Wang Y, Tao L, Mitchell E, Bogers WM, Doyle C, Bravery CA, Bergmeier LA, Kelly CG, Heeney JL, Lehner T: Generation of CD8 suppressor factor and beta chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques. Proc Natl Acad Sci USA 95:5223–5228, 1998

    Google Scholar 

  38. Heeney JL, Teeuwsen VJ, van Gils M, Bogers WM, De Giuli Morghen C, Radaelli A, Barnett S, Morein B, Akerblom L, Wang Y, Lehner T, Davis D: β-Chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci USA 95:10803–10808, 1998

    Google Scholar 

  39. Ahmed RK, Nilsson C, Wang Y, Lehner T, Biberfeld G, Thorstensson R: β-chemokines in Macaques vaccinated with live attenuated virus correlates with protection against SIV27 challenge. J Gen Virol 80:1569–1574, 1998

    Google Scholar 

  40. Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, Carlo DJ: Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 14:343–350, 1997

    Google Scholar 

  41. Moss RB, Wallace MR, Lanza P, Giermakowska W, Jensen FC, Theofan G, Chamberlin C, Richieri SP, Carlo DJ: In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clin Diag Lab Immunol 5:308–312, 1998

    Google Scholar 

  42. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringieri A, Santagostino E, Rappaport J, Feldman M, O'Brien SJ, Burny A, Gallo RC: C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 95:3857–3861, 1998

    Google Scholar 

  43. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, Mackay CR, Koup RA: Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of β-chemokines. Virology 244:66–73, 1998

    Google Scholar 

  44. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 2:412–417, 1996

    Google Scholar 

  45. Ullum H, Cozzi A, Victor J, Aladdin A, Phillips AN, Gerstoft J, Skinhej P, Pedersen BK: Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression. J Infect Dis 133:331–336, 1998

    Google Scholar 

  46. Tartakovsky B: Turner D, Vardinonn, Burke M, Yust I: Increased intracellular accumulation of macrophage inflammatory protein 1 beta and its decreased secretion correlate with advanced HIV disease. J Acquir Immune Defic Syndr Hum Retroviruses 20:420–422, 1999

    Google Scholar 

  47. Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams SA, Walker BD, Pasternack MS, Luster AD: β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 391:908–911, 1998

    Google Scholar 

  48. Price DA, Sewell AK, Dong T, Tan R, Goulder PJ, Rowland-Jones SL, Phillips RE: Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol 8:355–358, 1998

    Google Scholar 

  49. Wasik TJ, Bratosiewicz J, Wierzbicki A, Whiteman VE, Rutstein RR, Starr SE, Douglas SD, Kaufman D, Sison AV, Polansky M, Lischner HW, Kozbor D: Protective role of β-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. J Immunol 162:4355–4364, 1999

    Google Scholar 

  50. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Quillent C, Longhi R, Loverro P, Borgonovo B, Gaffi D, Carrow E, Malnati M, Lusso P, Siccardi AG, Lazzarin A, Beretta A: Antigendriven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 186:455–460, 1997

    Google Scholar 

  51. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, Devico AL, Gallo RC: Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA, in press

  52. Butz EA, Bevan MJ: Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 8:167–175, 1998

    Google Scholar 

  53. Pantaleo G, Soudeyns H, Demarest JF, Vaccarezza M, Graziosi C, Paolucci S, Daucher M, Cohen OJ, Denis F, Biddison WE, Sekaly RP, Fauci AS: Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 94:9848–9853, 1997

    Google Scholar 

  54. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, DeVico AL: Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 278:695–698, 1997

    Google Scholar 

  55. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA: Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186:1865–1872, 1997

    Google Scholar 

  56. Struyf S, De Meester I, Scharpe S, Lenaerts JP, Menten P, Wang JM, Proost P, Van Damme J: Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 28:1262–1271, 1998

    Google Scholar 

  57. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J: Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 273:7222–7227, 1998

    Google Scholar 

  58. Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, Honjo T, Nomoto A, Iwamoto A, Morimoto C, Nagai Y: Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1 alpha (SDF-1 alpha) and SDF-1 beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 95:6331–6336, 1998

    Google Scholar 

  59. Van Coillie E, Proost P, Van Aelst I, Struyf S, Polfliet M, De Meester I, Harvey DJ, Van Damme J, Opdenakker G: Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 37:12672–12680, 1998

    Google Scholar 

  60. Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpe S, Van Damme J, De Clercq E: CD26-processed RANTES(3–68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 39:175–187, 1998

    Google Scholar 

  61. Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, Mantovani A, Augustyns K, Bal G, Haemers A, Lambeir AM, Scharpe S, Van Damme J, De Meester I: Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 274:3988–3993, 1999

    Google Scholar 

  62. Nibbs RJ, Yang J, Landau NR, Mao JM, Graham GJ: LD78beta, A non-allelic variant of human MIP-1alpha (LD78ALPHA), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 274:17478–17483, 1999

    Google Scholar 

  63. Oravecz T, Pall M, Wang J, Roderiquez G, Ditto M, Norcross MA: Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J Immunol 159:4587–9452, 1997

    Google Scholar 

  64. Burns JM, Gallo RC, DeVico AL, Lewis GK: A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. J Exp Med 188:1917–1927, 1998

    Google Scholar 

  65. Amzazi S, Ylisastigui L, Bakri Y, Rabehi L, Gattegno L, Parmentier M, Gluckman JC, Benjouad A: The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state. Virology 252:96–105, 1998

    Google Scholar 

  66. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H: Tyrosine sulfation of the amino terminus of CCR-5 facilitates HIV-1 entry. Cell 96:667–676, 1999

    Google Scholar 

  67. Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, Caligiuri MA: Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 161:6433–6438, 1998

    Google Scholar 

  68. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, Monaco J, Ehler L, Mizell S, Jackson R, Li Y, Romano JW, Fauci AS: Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 102:223–231, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, Baltimore, Maryland, 21201-1192

    Robert C. Gallo, Robert C. Gallo, Alfredo Garzino-Demo & Anthony L. DeVico

Authors
  1. Robert C. Gallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfredo Garzino-Demo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony L. DeVico
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert C. Gallo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gallo, R.C., Garzino-Demo, A. & DeVico, A.L. HIV Infection and Pathogenesis: What About Chemokines?. J Clin Immunol 19, 293–299 (1999). https://doi.org/10.1023/A:1020539524373

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020539524373

Search

Navigation